Allergan and Adamas announced that all 4 dosage strengths of Namzaric (memantine and donepezil HCl) extended-release capsules are now available for the treatment of moderate to severe Alzheimer’s disease in patients stabilized on 10mg of donepezil HCl once daily.
The new strengths — 7mg/10mg and 21mg/10mg — and the new indication were approved by the Food and Drug Administration (FDA) in July 2016. Studies have demonstrated that combination therapy with Namenda XR(memantine HCl extended-release) and an AChEI (eg, Aricept) led to significantly superior improvement in cognition and global function vs. an AChEI alone.
Namzaric combines memantine HCl, an NMDA receptor antagonist, and donepezil HCl, an acetylcholinesterase inhibitor (AChEI). Memantine is postulated to exert its therapeutic effect through its action as a low to moderate affinity uncompetitive (open channel) NMDA receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels. Donepezil is postulated to exert its therapeutic effect by increasing the concentration of acetylcholine in the central nervous system through reversible inhibition of its hydrolysis by acetylcholinesterase.
Namzaric is now available as 7mg/10mg and 21mg/10mg extended-release capsules in 30-count bottles and as 14mg/10mg and 28mg/10mg extended-release capsules in 30- and 90-count bottles.
For more information call (800) 433-8871 or visit Namzaric.com.